Last update: Aug. 18, 2017


Low Risk for breastfeeding

Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

It promotes pancreatic insulin secretion by inhibiting the DPP-4 enzyme that degrades the intestinal hormone GLP-1 that is activated upon eating (EMA 2016, Scheen 2011).
Very low risk of hypoglycemia.
Recommended dose: one to two doses daily.

Since the last update we have not found published data on its excretion in breast milk.

Its pharmacokinetic data (EMA 2016, Scheen 2011) - low molecular weight and low percentage of binding to plasma proteins - makes it likely that significant amounts will pass into breast milk.

Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.

Diet, exercise, and breastfeeding improve blood sugar levels.

See below the information of these related products:


Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Vildagliptin in other languages or writings:


Main tradenames from several countries containing Vildagliptin in its composition:


Variable Value Unit
Oral Bioavail. 85 %
Molecular weight 303 daltons
Protein Binding 9,3 %
VD 1 l/Kg
Tmax 1 - 2 hours
T1/2 1,3 - 3 hours


  1. EMA. Vildagliptina. Ficha técnica. 2016 Full text (in our servers)
  2. EMA. Vildagliptin. Drug Summary 2016 Full text (in our servers)
  3. Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012 Abstract
  4. Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother. 2012 Abstract Full text (link to original source)
  5. He YL, Serra D, Wang Y, Campestrini J, Riviere GJ, Deacon CF, Holst JJ, Schwartz S, Nielsen JC, Ligueros-Saylan M. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2007 Abstract
  6. He YL, Sadler BM, Sabo R, Balez S, Wang Y, Campestrini J, Laurent A, Ligueros-Saylan M, Howard D. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet. 2007 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 from United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM